ATE326265T1 - Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte - Google Patents
Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichteInfo
- Publication number
- ATE326265T1 ATE326265T1 AT00978330T AT00978330T ATE326265T1 AT E326265 T1 ATE326265 T1 AT E326265T1 AT 00978330 T AT00978330 T AT 00978330T AT 00978330 T AT00978330 T AT 00978330T AT E326265 T1 ATE326265 T1 AT E326265T1
- Authority
- AT
- Austria
- Prior art keywords
- dhea
- calcitonin
- treatment
- bone mineral
- mineral density
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical group C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 title abstract 2
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract 2
- 239000011707 mineral Substances 0.000 title abstract 2
- 102000055006 Calcitonin Human genes 0.000 title 1
- 108060001064 Calcitonin Proteins 0.000 title 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title 1
- 229960004015 calcitonin Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102000017631 Calcitonin-like Human genes 0.000 abstract 2
- 108050005865 Calcitonin-like Proteins 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16508999P | 1999-11-12 | 1999-11-12 | |
| US09/710,729 US6605591B1 (en) | 1999-11-12 | 2000-11-10 | Treatment of subnormal bone mineral density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326265T1 true ATE326265T1 (de) | 2006-06-15 |
Family
ID=26861107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00978330T ATE326265T1 (de) | 1999-11-12 | 2000-11-13 | Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US6605591B1 (de) |
| EP (1) | EP1231983B1 (de) |
| JP (1) | JP2003514026A (de) |
| KR (1) | KR20020063183A (de) |
| CN (1) | CN1411386A (de) |
| AT (1) | ATE326265T1 (de) |
| AU (1) | AU784160B2 (de) |
| BR (1) | BR0015534A (de) |
| CA (1) | CA2390431A1 (de) |
| DE (1) | DE60028074D1 (de) |
| IL (1) | IL149532A0 (de) |
| MX (1) | MXPA02004776A (de) |
| NO (1) | NO20022246L (de) |
| NZ (1) | NZ518791A (de) |
| RU (1) | RU2002115815A (de) |
| WO (1) | WO2001035975A2 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605591B1 (en) * | 1999-11-12 | 2003-08-12 | Genelabs Technologies, Inc. | Treatment of subnormal bone mineral density |
| US8639009B2 (en) * | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
| US7660453B2 (en) | 2000-10-11 | 2010-02-09 | Imaging Therapeutics, Inc. | Methods and devices for analysis of x-ray images |
| US8000766B2 (en) | 2001-05-25 | 2011-08-16 | Imatx, Inc. | Methods to diagnose treat and prevent bone loss |
| US8965075B2 (en) * | 2002-09-16 | 2015-02-24 | Imatx, Inc. | System and method for predicting future fractures |
| US7840247B2 (en) * | 2002-09-16 | 2010-11-23 | Imatx, Inc. | Methods of predicting musculoskeletal disease |
| US8600124B2 (en) * | 2004-09-16 | 2013-12-03 | Imatx, Inc. | System and method of predicting future fractures |
| EP1605824A2 (de) | 2003-03-25 | 2005-12-21 | Imaging Therapeutics, Inc. | Verfahren zur kompensation der bildgebenden technik bei der bearbeitung von röntgenaufnahmen |
| US20050014734A1 (en) * | 2003-07-18 | 2005-01-20 | Genovate Biotechnology Co., Ltd. | Modulation of interleukin-10 by DHEA |
| US20080058613A1 (en) * | 2003-09-19 | 2008-03-06 | Imaging Therapeutics, Inc. | Method and System for Providing Fracture/No Fracture Classification |
| WO2009146490A1 (en) * | 2008-06-03 | 2009-12-10 | John Ray Biffin | A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k |
| US20110092426A1 (en) * | 2007-08-09 | 2011-04-21 | Novartis Ag | Oral calcitonin compositions and applications thereof |
| US8939917B2 (en) | 2009-02-13 | 2015-01-27 | Imatx, Inc. | Methods and devices for quantitative analysis of bone and cartilage |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
| WO1994008589A1 (en) | 1992-10-09 | 1994-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of systemic lupus erythematosus with dehydroepiandrosterone |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| AU743121B2 (en) | 1996-11-25 | 2002-01-17 | Merck & Co., Inc. | Androgenic and bisphosphonic agents coadministered to treat diseases |
| KR20000071039A (ko) * | 1997-02-13 | 2000-11-25 | 비숍 찰스 더블유. | 비타민 ｄ 화합물의 표적화된 치료학적 전달 |
| RU2220727C2 (ru) | 1999-03-18 | 2004-01-10 | Дженелабс Текнолоджис, Инк. | Композиция, содержащая дегидроэпиандростерон, и способы ее изготовления и применения |
| US7045513B1 (en) | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| US6605591B1 (en) * | 1999-11-12 | 2003-08-12 | Genelabs Technologies, Inc. | Treatment of subnormal bone mineral density |
-
2000
- 2000-11-10 US US09/710,729 patent/US6605591B1/en not_active Expired - Fee Related
- 2000-11-13 NZ NZ518791A patent/NZ518791A/en unknown
- 2000-11-13 KR KR1020027006101A patent/KR20020063183A/ko not_active Ceased
- 2000-11-13 WO PCT/US2000/030131 patent/WO2001035975A2/en not_active Ceased
- 2000-11-13 RU RU2002115815/14A patent/RU2002115815A/ru not_active Application Discontinuation
- 2000-11-13 AU AU15802/01A patent/AU784160B2/en not_active Ceased
- 2000-11-13 JP JP2001537966A patent/JP2003514026A/ja not_active Withdrawn
- 2000-11-13 EP EP00978330A patent/EP1231983B1/de not_active Expired - Lifetime
- 2000-11-13 BR BR0015534-9A patent/BR0015534A/pt not_active IP Right Cessation
- 2000-11-13 AT AT00978330T patent/ATE326265T1/de not_active IP Right Cessation
- 2000-11-13 DE DE60028074T patent/DE60028074D1/de not_active Expired - Lifetime
- 2000-11-13 IL IL14953200A patent/IL149532A0/xx unknown
- 2000-11-13 MX MXPA02004776A patent/MXPA02004776A/es active IP Right Grant
- 2000-11-13 CN CN00817384A patent/CN1411386A/zh active Pending
- 2000-11-13 CA CA002390431A patent/CA2390431A1/en not_active Abandoned
-
2002
- 2002-05-10 NO NO20022246A patent/NO20022246L/no not_active Application Discontinuation
-
2003
- 2003-02-13 US US10/367,218 patent/US6854468B2/en not_active Expired - Fee Related
-
2004
- 2004-12-28 US US11/024,557 patent/US7612034B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6605591B1 (en) | 2003-08-12 |
| US20030158159A1 (en) | 2003-08-21 |
| MXPA02004776A (es) | 2003-01-28 |
| WO2001035975A2 (en) | 2001-05-25 |
| JP2003514026A (ja) | 2003-04-15 |
| US7612034B2 (en) | 2009-11-03 |
| NO20022246D0 (no) | 2002-05-10 |
| US6854468B2 (en) | 2005-02-15 |
| CA2390431A1 (en) | 2001-05-25 |
| RU2002115815A (ru) | 2004-02-27 |
| WO2001035975A3 (en) | 2001-12-27 |
| AU784160B2 (en) | 2006-02-16 |
| NZ518791A (en) | 2004-03-26 |
| EP1231983B1 (de) | 2006-05-17 |
| US20050113301A1 (en) | 2005-05-26 |
| AU1580201A (en) | 2001-05-30 |
| IL149532A0 (en) | 2002-11-10 |
| EP1231983A2 (de) | 2002-08-21 |
| CN1411386A (zh) | 2003-04-16 |
| BR0015534A (pt) | 2002-07-02 |
| KR20020063183A (ko) | 2002-08-01 |
| NO20022246L (no) | 2002-07-03 |
| DE60028074D1 (de) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE326265T1 (de) | Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte | |
| ATE293883T1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| PL332413A1 (en) | Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals | |
| DE69726245D1 (de) | Befeuchtungsgerät zur Behandlung von Atemstillstand im Schlaf | |
| DE69733611D1 (de) | Verfahren und potenzierte zusammensetzung zur behandlung von migräne | |
| ATE510542T1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
| ATE247950T1 (de) | Fentanylzusammensetzung zur behandlung von akutem schmerz | |
| BR9911748A (pt) | Artigo absorvente, inserto para ser colocado em uma peça de vestuário do usuário, artigo descartável e processo para aumentar a capacidade de remoção de excreções corpóreas da pele de um usuário | |
| DK0880350T3 (da) | Behandling af dissemineret sklerose | |
| BR9811780A (pt) | Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente | |
| WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
| ATE303817T1 (de) | Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| TW200505473A (en) | Compositions and methods for treatment of psoriasis | |
| DE69008258D1 (de) | S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates. | |
| ATE526980T1 (de) | Zusammensetzungen und verfahren zur heilung von nervengeweben | |
| ATE226058T1 (de) | Verwendung von lysin zur behandlung des haarausfalls | |
| GB2331301C (en) | Galanin | |
| AU2003248816A8 (en) | Composition for lessening malodors during hair treatment and hair removal and method of use | |
| ATE236169T1 (de) | Heterocyclisch kondensierte morphinoid-derivate | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE282398T1 (de) | Verfahren zum dauerwellen von menschlichen haaren | |
| DE60129725D1 (de) | Schwefel analoge von 21-hydroxy-6,19-oxidoprogesteronen (21oh-6op) zur behandlung von glucocorticoidüberschuss | |
| DE69736955D1 (de) | Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen | |
| ATE318612T1 (de) | Methoden und zusammensetzungen zur behandlung der hyperlipidämie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |